Table 1 Demographics of studied patients

From: Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

 

N (%)

Patients

90 (100.0)

Sex

 Male

54 (60.0)

 Female

36 (40.0)

Age

 Median (years)

69

 Range (years)

45–86

 <65 years

31 (34.4)

 ⩾65 years

59 (65.6)

Stage (UICC)a

 I

3 (3.3)

 II

30 (33.3)

 III

15 (16.7)

 IV

42 (46.7)

Systemic therapy

 Unfollowedb

56 (62.2)

 Followedc

34 (37.8)

Controls

33

  1. Abbreviations: BV=bevacizumab; CRC=colorectal cancer; UICC=Union for International Cancer Control.
  2. aAt enrolment.
  3. bPatients with primary CRC who underwent tumour resection and were not followed up for outcome of any further treatment.
  4. cPatients with primary or relapsed CRC who received BV-containing therapy and were followed up for treatment outcome.
Back to article page